TY - JOUR
T1 - Beta(2)-adrenoceptors increase translocation of GLUT4 via GPCR kinase sites in the receptor C-terminal tail
AU - Dehvari, Nodi
AU - Hutchinson, Dana
AU - Nevzorova, Julia
AU - Dallner, Olof
AU - Sato, Masaaki
AU - Kocan, Martina
AU - Merlin, Jon
AU - Evans, Bronwyn
AU - Summers, Roger
AU - Bengtsson, Tore
PY - 2012
Y1 - 2012
N2 - Background and purpose: beta-Adrenoceptor (beta-AR) stimulation induces glucose uptake in several insulin-sensitive tissues, by poorly understood mechanisms. Experimental approach: We used a model system in CHO-K1 (Chinese Hamster ovary K1) cells expressing the human beta(2) -AR and glucose transporter 4 (GLUT4) to investigate the signalling mechanisms involved. Key results: In CHO-K1 cells there was no response to beta-AR agonists. The introduction of beta(2) -ARs and GLUT4 into these cells caused increased glucose uptake in response to beta-AR agonists. GLUT4 translocation occurred in response to insulin and beta(2) -AR stimulation, although the key insulin signalling intermediate Akt was not phosphorylated in response to beta(2) -AR stimulation. Truncation of the C-terminus of the beta(2) -AR at position 349 to remove known phosphorylation sites for G protein-coupled receptor kinases (GRKs) or at position 344 to remove an additional protein kinase A (PKA) site together with the GRK phosphorylation sites did not significantly affect cyclic AMP accumulation but decreased beta(2) -AR stimulated glucose uptake. Furthermore, inhibition of GRK by transfection of betaARKct inhibited beta(2) -AR-mediated glucose uptake and GLUT4 translocation, and over-expression of a kinase-dead GRK2 mutant (GRK2 K220R) also inhibited GLUT4 translocation. Introducing beta(2) -AR lacking phosphorylation sites for GRK or PKA demonstrated that the GRK sites, but not the PKA sites, were necessary for GLUT4 translocation. Conclusions and implications: Glucose uptake in response to activation of beta(2) -ARs involves translocation of GLUT4 in this model system. The mechanism is dependent on the C-terminus of the beta(2) -AR, requires GRK phosphorylation sites, and involves a signalling pathway distinct from that stimulated by insulin.
AB - Background and purpose: beta-Adrenoceptor (beta-AR) stimulation induces glucose uptake in several insulin-sensitive tissues, by poorly understood mechanisms. Experimental approach: We used a model system in CHO-K1 (Chinese Hamster ovary K1) cells expressing the human beta(2) -AR and glucose transporter 4 (GLUT4) to investigate the signalling mechanisms involved. Key results: In CHO-K1 cells there was no response to beta-AR agonists. The introduction of beta(2) -ARs and GLUT4 into these cells caused increased glucose uptake in response to beta-AR agonists. GLUT4 translocation occurred in response to insulin and beta(2) -AR stimulation, although the key insulin signalling intermediate Akt was not phosphorylated in response to beta(2) -AR stimulation. Truncation of the C-terminus of the beta(2) -AR at position 349 to remove known phosphorylation sites for G protein-coupled receptor kinases (GRKs) or at position 344 to remove an additional protein kinase A (PKA) site together with the GRK phosphorylation sites did not significantly affect cyclic AMP accumulation but decreased beta(2) -AR stimulated glucose uptake. Furthermore, inhibition of GRK by transfection of betaARKct inhibited beta(2) -AR-mediated glucose uptake and GLUT4 translocation, and over-expression of a kinase-dead GRK2 mutant (GRK2 K220R) also inhibited GLUT4 translocation. Introducing beta(2) -AR lacking phosphorylation sites for GRK or PKA demonstrated that the GRK sites, but not the PKA sites, were necessary for GLUT4 translocation. Conclusions and implications: Glucose uptake in response to activation of beta(2) -ARs involves translocation of GLUT4 in this model system. The mechanism is dependent on the C-terminus of the beta(2) -AR, requires GRK phosphorylation sites, and involves a signalling pathway distinct from that stimulated by insulin.
UR - http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2011.01647.x/pdf
U2 - 10.1111/j.1476-5381.2011.01647.x
DO - 10.1111/j.1476-5381.2011.01647.x
M3 - Article
SN - 0007-1188
VL - 165
SP - 1442
EP - 1456
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 5
ER -